Skip to content
glp1.howSign in

Using GLP-1s

Dosing, side effects, and tracking progress while using a GLP-1 medication.

DosingSide EffectsTracking Progress

133 articles · updated Oct 1

Guides

New
guide
Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
New
guide
Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
guide
Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.
guide
Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
STEP 1, SURMOUNT-4, SELECT, LEADER: GLP-1 trial names get quoted everywhere, usually without context. This reference page lists 205 named, completed GLP-1 trials in one place, grouped by drug and by question, with what each one tested, who sponsored it, its headline result, and a link to the published paper. It also lists the trials that finished but have not reported, and shows who paid for the research.
guide
Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found
If you've lost weight on Zepbound or Wegovy and want off the weekly injection, can a daily pill hold your results? One randomized trial has now tested exactly that, and Wegovy users also have an on-label switch to Wegovy tablets. This guide covers what the trial found, how much weight people kept, what the switch felt like, and the big question the trial didn't answer.
guide
Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show
Some people space their weekly GLP-1 to every 10 or 14 days to save money or ease off. This guide covers what that does to drug levels, what the two small studies found, why that isn't proof yet, and the risks worth planning around with a prescriber.
guide
A new pancreas study on GLP-1 drugs: what it actually shows
A March 2026 Salk Institute study found a molecular switch, phosphorylation of a protein called Med14, that helps pancreatic beta cells carry out a broad gene response to prolonged GLP-1 exposure. It's a peer-reviewed finding from rat cells and mouse islets, with no human confirmation yet. What it found, what it means, and what it doesn't tell us.
guide
Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
Researchers now describe four "phenotypes" of obesity (hungry brain, hungry gut, emotional hunger, and slow burn), and early evidence suggests they help explain why the same GLP-1 produces very different results in different people. One newly described "hungry gut" subtype lost nearly twice as much weight on tirzepatide. What the phenotypes are, what the studies show, and what to know before paying for a phenotype test.
guide
Does loose skin throw off your DXA, BIA, or Seca body-composition results?
Loose skin is fat-free tissue that body-composition scanners have no separate box for, so after large weight loss it can nudge your DXA "lean mass" up and your body-fat % down, and it complicates BIA and Seca readings too. This guide covers how each method (DXA, BIA/Seca, MRI) handles loose skin, how they rate for a body carrying a lot of it, and how to read your results anyway.
guide
What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
The American Diabetes Association's Standards of Care is the reference most US clinicians follow, and it now puts GLP-1 medications at the center of treating diabetes with obesity. It names GLP-1s as the preferred obesity medication in type 2 diabetes, sets realistic weight-loss targets, and says the highest dose isn't always the goal. The headline 2026 change: for the first time, the ADA cautiously supports GLP-1 therapy for people with type 1 diabetes and obesity, with important safety guardrails.
guide
GLP-1 super-responders (and non-responders): why weight loss varies so much
On the same drug at the same dose, one person loses 25% of their body weight and another loses almost nothing. In the tirzepatide trials, half or more of people on the higher doses lost 20% or more, but a large real-world analysis found only about 1 in 8 lost more than 15% in a year, while nearly half lost under 5%. What predicts a strong response (early weight change, drug choice, sex, diabetes, biology), why real-world results trail the trials, and what to do if you're not responding.
guide
Reading your DXA results over time: tracking fat vs. lean mass on a GLP-1
Your second DXA report is only useful if you can tell real change from measurement noise. This guide shows how to read the key numbers over time (fat mass, lean mass, body fat %, visceral fat, bone density), what a good GLP-1 trajectory looks like, why small changes may be noise, and how to shift the fat-to-lean loss ratio.
guide
Loose skin after GLP-1 weight loss: what actually helps and what's hype
Loose or excess skin on the belly, arms, and thighs is a common worry after large GLP-1 weight loss. What the evidence supports (gradual loss, muscle, nutrition, time), which creams and wraps promise more than they deliver, and when surgery is the only real fix.
guide
Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
Liraglutide (Victoza for diabetes, Saxenda for weight) was the first GLP-1 approved for weight management. It's a daily injection with a half-life of about 13 hours and generally more modest weight loss than the weekly drugs. What makes it different, and why some people still choose it.
guide
What is suppression, satiation, and satiety on a GLP-1?
GLP-1 medications change appetite in three related but distinct ways: suppression, satiation, and satiety. What each means and what to expect.
guide
Safe sharps disposal for GLP-1 injectors
Every GLP-1 injection ends with a needle you have to put somewhere. This guide walks through the FDA's two-step system: a proper sharps container (or an acceptable heavy-duty household stand-in), the short list of things never to do with a used needle, how to find your community's disposal rules, and what changes when you travel.
guide
Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses
On a U-100 insulin syringe, "units" measure volume: 100 units make 1 mL. Your vial's concentration is what turns a prescribed mg dose into a unit count. This walkthrough teaches the arithmetic with worked examples at different concentrations, explains the dosing errors the FDA has documented, and gives a checklist to go through with your pharmacist. It teaches you to read the syringe. It does not prescribe doses.
guide
GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk
A GLP-1 on its own rarely causes low blood sugar, but pairing it with insulin or a sulfonylurea meaningfully raises the risk. Why, how to recognize hypoglycemia, and what to settle with your prescriber before any dose changes.
guide
Stopping a GLP-1: tapering, weight regain, and restarting safely
Whether by choice or circumstance, most people stop a GLP-1 at some point. This guide covers what stopping can and can't get you, what withdrawal trials and real-world data show about weight regain and lost health benefits, whether a GLP-1 is really a medication for life, how tapering compares, and why restarting after a gap usually means re-titrating.
guide
Do GLP-1 receptors "burn out"? What long-term use actually does
A common worry is that GLP-1 receptors "burn out" with long-term use: that the drug stops working or permanently damages your natural system. Where the idea comes from, what two-year trial data show, which effect really does fade (the slowing of stomach emptying), why a plateau is a new equilibrium, and what happens to your own appetite when you stop.
guide
Common mistakes people make on GLP-1 medications — and how to avoid them
Most GLP-1 setbacks come from a short list of avoidable mistakes: treating it as a quick fix, neglecting protein and strength training, rushing the dose, under-hydrating, putting up with side effects instead of managing them, and going it alone. This guide covers the common ones, why they matter, and where to find the fix for each.
guide
Shot day routines: how the GLP-1 community builds a weekly injection ritual
Once-weekly dosing turns "shot day" into a small ritual. People build routines around it: picking the right day, warming the pen to reduce sting, rotating sites, eating lighter, logging everything, and heading off side effects before they start. This is a tour of the common routines GLP-1 users swear by, and the reasons behind the ones worth copying.
guide
GLP-1 microdosing: what it means, why people do it, and what the evidence actually says
"Microdosing" GLP-1s is all over social media: using much smaller doses than the label calls for, for weight maintenance, side-effect avoidance, cost, or vague wellness claims. What the term means, the real medicine it borrows from, why no clinical trial has tested it, the specific risks of the DIY version, and how to have a lower-dose conversation with your prescriber instead.
guide
What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
The formula used to diagnose obesity was invented in the 1830s by an astronomer studying populations, not patients, and a lot of what we assume about obesity rests on tools and ideas never designed for the job. How the definition moved from moral failing to medical diagnosis, how it's diagnosed today, why major medical bodies classify it as a disease, why it's considered chronic, and where the stigma comes from.
guide
Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
You can raise your own GLP-1 with protein, fermentable fiber, and exercise, and that part is real. What doesn't hold up is the implied equivalence with the medications. This guide covers what nudges your natural GLP-1, why your body clears it in minutes while the drugs hold it for a week, and why "natural boosting" works as a foundation for treatment and can't replace it.
guide
GLP-1 myths vs. facts: what the media and social feeds get wrong
A plain-language, evidence-checked look at the most common claims about GLP-1 medications in the news and on social media: which are false, which are true, and which are still unsettled, with the studies behind each verdict.
guide
Common GLP-1 side effects and how to manage them
Most GLP-1 side effects are digestive, worst right after a dose increase, and manageable with a few practical habits. What to expect, what helps with nausea and constipation, and the red-flag symptoms that mean you should call a doctor now.
guide
What to realistically expect on a GLP-1
A GLP-1 doesn't work like a switch. Expect weeks of dose titration before much happens, then average loss of roughly 1% of body weight a month in the big trials, wide variation between fast and slow responders, an expected plateau, and a treatment you plan to stay on long term.
guide
How GLP-1 medications work, in plain language
Semaglutide and tirzepatide copy hormones your gut already makes after a meal. This guide explains what those hormones do, why the medications quiet hunger and 'food noise,' what the second hormone in tirzepatide adds, and how the same signal that cuts appetite can also cause nausea.
guide
The cardiovascular benefits of GLP-1 medications
Several GLP-1 medications have been tested in large cardiovascular outcomes trials, and they lowered the combined rate of heart attack, stroke and cardiovascular death. The pooled data show clear drops in cardiovascular death, heart attacks and heart failure, but not a clear drop in stroke. What the trials found, who was in them, and what they don't tell you.
guide
The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens
The pen in your fridge is the product of a century of injection-device development. How GLP-1 delivery devices evolved, which brands use vials, multi-dose pens or single-dose auto-injectors, why pens are easier and safer than vials, and how auto-injectors differ from dial-a-dose pens.
guide
The history of GLP-1 medications: every approved drug, who made them, and what's coming next
The GLP-1 drug class is 20 years old. It began with a twice-daily injection derived from Gila monster venom. This timeline lists every U.S.-approved GLP-1 drug and its maker, which ones are no longer sold, how they compare, and what's still in the pipeline.
guide
Tapering vs. staying on a maintenance dose for long-term use
Long-term GLP-1 treatment doesn't have to mean staying at your highest effective dose indefinitely. This guide compares tapering to a lower maintenance dose with stopping altogether or holding steady.
guide
Does increasing your dose always mean more weight loss?
A weight loss plateau doesn't automatically mean you need a higher dose, and a higher dose doesn't automatically break a plateau. How dose and weight loss relate, including the new 7.2 mg Wegovy dose, and what else to check first.
guide
When and why a prescriber might slow down your titration
You can stay at a dose step longer than the standard titration schedule says. This guide covers what the labels allow, the common reasons prescribers extend a step, and how to raise it.
guide
Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens
Brand-name GLP-1 pens measure the dose for you. Compounded versions usually come as a vial and syringes, so you measure it yourself. Why that raises the stakes on accuracy, what to ask your pharmacy, and where compounding stands after the shortages ended.
guide
Storing and traveling with your GLP-1 medication
Refrigeration rules, room-temperature windows, and flying with an injectable medication all raise practical questions. This guide gives the label storage windows for each GLP-1 pen and pill, a few habits that protect your medication, and what to plan before a trip.
guide
Pen types and injection technique across GLP-1 brands
Not all GLP-1 pens work the same way. Some are pre-set single-dose auto-injectors; others need a needle attached, a dose set, and a priming step. A brand-by-brand comparison and the technique habits that apply to every pen.
guide
Switching between diabetes and weight-management dosing of the same drug
Ozempic and Wegovy share an active ingredient, as do Mounjaro and Zepbound, but switching between them isn't always a straight swap. Semaglutide's two dose ladders split after 1 mg; tirzepatide's ladder is identical, but the label and coverage still change.
guide
Why some people stay on a lower maintenance dose
Staying below the maximum labeled dose isn't a compromise or a sign of "not trying hard enough." For many people it's the clinically appropriate outcome. The reasons, and what the trials show about lower doses.
guide
What happens if you accidentally take a double dose
Injecting twice, or using the wrong-strength pen, does happen. What to expect in the days after, when to call your prescriber or Poison Help, and how to keep it from happening again.
guide
What to do if you miss a GLP-1 dose
Missed-dose rules depend on how close you are to your next scheduled dose and on the drug, and getting it wrong in either direction carries real risk. The label rules for weekly injections, daily injections and pills, and when a missed dose means restarting lower.
guide
What "maintenance dose" actually means and how it's decided
Your maintenance dose is the dose that works for you, which isn't always the highest dose on the label. This guide explains how that dose gets chosen, what the trials show about higher and lower maintenance doses, and when it can change.
guide
Understanding your specific drug's dose ladder
Semaglutide, tirzepatide, dulaglutide, liraglutide and orforglipron each have their own titration ladder, with different starting doses, step sizes and timing. A side-by-side table of the injections and pills, and why you should confirm your own schedule with your prescriber.
guide
How GLP-1 titration schedules work
GLP-1 doses don't start at their effective target. They climb in deliberate steps. Why titration is structured this way, what it means for side effects, why you re-titrate after a break, and what the labels allow if the pace feels too fast.
guide
GLP-1 side effect timeline: what to expect at each stage
GLP-1 side effects cluster around starting treatment and each dose increase, then tend to ease. A general timeline, based on trial data, to help you know what's typical and when.
guide
Anxiety around eating or body image emerging during GLP-1 treatment
For some people, GLP-1 treatment brings up new or returning anxiety about food and body image, even without a prior diagnosis. What the evidence shows, how to recognize it, and what to do.
guide
Mood changes and anhedonia on a GLP-1: what the research shows
Reports of mood changes and blunted pleasure on GLP-1 medications drew regulatory attention. What the evidence shows on suicidality and anhedonia, and when to take a mood change seriously.
guide
The thyroid C-cell tumor warning: what it means and who it applies to
Most GLP-1 medications carry a boxed warning about thyroid C-cell tumors, based on rodent studies. What the warning means, who it applies to, and what is known versus precautionary.
guide
Kidney injury risk from dehydration on a GLP-1
Most reported cases of acute kidney injury on a GLP-1 follow dehydration from nausea, vomiting, or diarrhea; rarer cases have other causes. How the dehydration chain works, how to interrupt it early, and why overall kidney risk isn't raised.
guide
Pancreatitis and GLP-1 medications: warning signs and when to seek emergency care
Pancreatitis is rare on GLP-1 medications but serious, and it's one of the few side effects that is a medical emergency. What the evidence shows about risk, and which symptoms mean you should seek care immediately.
guide
Gallbladder disease and gallstones on a GLP-1
Gallbladder and biliary disease is one of the better-documented, more clinically significant risks of GLP-1 treatment, driven partly by the medication and partly by rapid weight loss. How big the risk is and which symptoms need prompt care.
guide
Fatigue and low energy during GLP-1 titration
Fatigue is a recognized GLP-1 side effect. Many people notice it early in treatment or after a dose increase, though trials haven't tracked its timing. It usually has causes you can find and fix, such as eating too little, dehydration, or ongoing GI symptoms.
guide
GLP-1 face: prevention, skincare, and what it actually signals
"GLP-1 face" isn't a medical diagnosis, but a hollowed look during rapid weight loss is a real, common concern. What causes it, what might help, and when it's more than cosmetic.
guide
Hair loss on a GLP-1: what the evidence actually shows
Hair loss is listed as an adverse reaction on the Zepbound label, and recent research shows it's a real, well-documented effect. It is most plausibly tied to rapid weight loss, and the most common type is temporary. What the evidence shows and what can help.
guide
Injection site reactions: what's normal and what to watch for
Redness, mild swelling, or a small bruise at the injection site are common and usually harmless. How to tell normal reactions from ones that need a call to your prescriber, and how to reduce them.
guide
Constipation on a GLP-1: why it happens and how to manage it
Constipation is one of the most common GLP-1 side effects and lasts longer than the others, and it's closely tied to the fiber gap covered in our nutrition guide. Why it happens and how to manage it.
guide
Managing nausea on a GLP-1: practical strategies
Nausea is the most common GLP-1 side effect. Practical eating and timing strategies to manage it, and when medication support makes sense.
guide
GI side effects on a GLP-1: nausea, vomiting, diarrhea, and constipation
Gastrointestinal symptoms are by far the most common GLP-1 side effect. How common each one is, what's typical during titration, what tends to fade, and when to call your prescriber.
guide
DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one
The scale can't tell you if you're losing fat or muscle. A DXA scan can. This guide covers what a DXA scan measures, how it compares to BIA devices like Seca and InBody (including home scales), how often to get one, and where to get scanned.

Conversation guides

discussion guide
Talking to your doctor about side effects that aren't improving
Some GI side effects fade with time and others don't. How to tell the difference, and how to bring the stubborn ones up with your prescriber instead of toughing them out.
discussion guide
Talking to your doctor about stopping or tapering off treatment
Thinking about stopping because of cost, side effects, or reaching your goal? Have that conversation with your prescriber on purpose, instead of quietly not refilling.
discussion guide
Talking to your doctor about switching GLP-1 medications
Not every GLP-1 works equally well for every person. How to raise a switch to a different drug, dose, or formulation with your prescriber, and what to ask about titration and coverage.
discussion guide
Talking to your doctor about GLP-1 medications
How to prepare for the appointment and the questions worth asking, so you get a productive conversation.

Glossary terms

  • Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
  • Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
  • Oral semaglutide — Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.
  • Pharmacovigilance — The science and practice of detecting, assessing, and preventing adverse effects of medications once they are in real-world use, after clinical trials end.
  • Least significant change (DXA precision) — The minimum difference between two scans on the same machine that can be considered a true change rather than measurement error, usually reported as a percentage or in grams.
  • Telogen effluvium — A temporary form of diffuse hair shedding that begins two to three months after a physical stressor — including rapid weight loss — pushes many hair follicles into their resting phase at once.
  • FAERS (FDA Adverse Event Reporting System, now AEMS) — The FDA's database of voluntary side-effect reports from patients, clinicians, and manufacturers, used to detect safety signals after a drug is on the market. In March 2026 it became part of the FDA Adverse Event Monitoring System (AEMS).
  • Cardiovascular outcomes trial (CVOT) — A large randomized trial built specifically to measure a drug's effect on heart attacks, strokes, and cardiovascular death, as opposed to surrogate markers like blood sugar or weight.
  • MACE (major adverse cardiovascular events) — A composite trial endpoint bundling cardiovascular death, non-fatal heart attack, and non-fatal stroke into a single outcome.
  • U-100 insulin syringe (units) — A syringe marked in "units" where 100 units equal 1 mL — designed for U-100 insulin but commonly used to draw compounded GLP-1 doses from vials.
  • Lowest effective dose — The smallest dose of a medication that produces the intended benefit with tolerable side effects. It is a standard prescribing principle.
  • Boxed warning — The FDA's strongest prescription-drug warning, set in a black-bordered box at the top of the label to flag a serious or life-threatening risk.
  • Sulfonylurea — A class of oral type 2 diabetes medications (e.g. glipizide, glimepiride, glyburide) that stimulate the pancreas to release insulin regardless of blood sugar level.
  • Hypoglycemia — Blood sugar that drops below the normal range (typically under 70 mg/dL), causing shakiness, sweating, confusion, or worse.
  • MEN 2 (multiple endocrine neoplasia type 2) — An inherited syndrome that raises the risk of medullary thyroid carcinoma and is a contraindication to most GLP-1 medications.
  • Medullary thyroid carcinoma (MTC) — A rare thyroid cancer arising from the thyroid's C cells; a personal or family history of it is a contraindication to GLP-1 medications.
  • Lipohypertrophy — A rubbery lump of thickened fatty tissue under the skin caused by repeated injections in the same spot.
  • DPP-4 — Dipeptidyl peptidase-4, the enzyme that rapidly breaks down the body's own GLP-1 within minutes.
  • Gastric emptying — The rate at which the stomach passes its contents into the small intestine, which GLP-1 medications slow down.
  • Saxenda — A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for chronic weight management and made by Novo Nordisk.
  • Victoza — A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for type 2 diabetes and made by Novo Nordisk.
  • Liraglutide — A first-generation GLP-1 receptor agonist taken as a daily injection, sold as Victoza for type 2 diabetes and Saxenda for weight management, and now also as a US generic.
  • Zofran — Brand name for ondansetron, an anti-nausea medication sometimes prescribed alongside GLP-1 medications to manage nausea side effects.
  • Foundayo — Eli Lilly's brand name for oral orforglipron, a GLP-1 medication for adults with obesity or excess weight plus weight-related medical problems.
  • Zepbound — Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
  • Mounjaro — Eli Lilly's brand name for injectable tirzepatide, FDA-approved for type 2 diabetes (adults and children 10+) and for cardiovascular risk reduction in high-risk adults with type 2 diabetes.
  • Wegovy — Novo Nordisk's brand name for semaglutide (weekly injection or, since December 2025, a daily pill), FDA-approved for chronic weight management and heart-risk reduction, and as an injection for MASH liver disease.
  • Ozempic — Novo Nordisk's brand name for semaglutide for type 2 diabetes, sold as a weekly injection and, since May 2026 in the US, as daily Ozempic tablets.
  • Effectiveness — How well a medication performs in everyday, real-world use, as opposed to the controlled conditions of a clinical trial.
  • Efficacy — How well a medication performs under ideal, controlled conditions — typically measured in clinical trials.
  • Peptide — A short chain of amino acids: the molecular structure of the natural hormones GLP-1 medications mimic, and of most of the medications themselves.
  • Retatrutide — An investigational triple agonist medication (GLP-1, GIP, and glucagon) developed by Eli Lilly, in phase 3 trials and not yet FDA-approved as of September 2026.
  • Glucagon — A hormone that raises blood sugar by triggering the liver to release stored glucose — the functional counterpart to insulin, and an emerging target in newer GLP-1-class medications.
  • InBody scan — A popular brand of bioelectrical impedance device used to measure body composition, often found in gyms and clinics.
  • Seca scan — A medical-grade body composition measurement device made by Seca, using bioelectrical impedance to estimate fat and lean mass.
  • BIA — Bioelectrical impedance analysis — a body composition measurement method that estimates fat and lean mass by sending a small electrical current through the body.
  • Food noise — A colloquial term for persistent, intrusive thoughts about food — commonly reported to diminish significantly on GLP-1 medications.
  • Agonist — A general pharmacology term for any substance that activates a receptor to produce a biological response.
  • Slow responder — A patient who experiences minimal appetite suppression or weight loss at typical doses, often requiring longer titration or higher doses to see results.
  • Fast responder — A patient who experiences significant appetite suppression and weight loss quickly, often at lower doses, after starting a GLP-1 medication.
  • Novo Nordisk — A Danish pharmaceutical company that makes semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), among other medications.
  • Eli Lilly — A U.S.-based pharmaceutical company that makes tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo), among other medications.
  • Tirzepatide — A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • Semaglutide — A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Bariatric surgery — Weight-loss surgery (such as gastric bypass or sleeve gastrectomy) that alters the digestive system, often compared to GLP-1 medications as a treatment option.
  • GLP-1 receptor agonist vs. dual agonist — A comparison between single-hormone GLP-1 drugs (e.g. semaglutide) and dual-hormone GLP-1/GIP drugs (e.g. tirzepatide).
  • Pancreatitis — Inflammation of the pancreas — a rare but serious potential side effect of GLP-1 medications requiring immediate medical attention.
  • Weight regain — The return of lost weight, commonly seen after stopping a GLP-1 medication.
  • Weight loss plateau — A period during treatment when weight loss slows or stalls despite continued medication use.
  • DXA scan — A specialized X-ray scan that measures body composition, including fat mass, lean mass, and bone density.
  • Comorbidity — A health condition that exists alongside a primary condition, for example type 2 diabetes, high blood pressure, or sleep apnea occurring with obesity.
  • BMI — Body mass index: a weight-to-height ratio commonly used as a screening threshold for obesity and GLP-1 eligibility.
  • A1C — A blood test measuring average blood sugar over the past 2-3 months, used to diagnose and monitor diabetes.
  • GLP-1 face — A colloquial term for facial volume loss and skin laxity that can accompany rapid, significant weight loss on GLP-1 medications.
  • Gastroparesis — A diagnosis of abnormally delayed stomach emptying with persistent symptoms. GLP-1 medications cause mild, temporary slowing in many people, which is not the same thing, but the Wegovy label says it is not recommended in severe gastroparesis.
  • Appetite suppression — A reduction in the drive or desire to eat, distinct from the fullness felt during or after a meal.
  • Satiety — The sense of fullness that persists between meals, delaying the return of hunger.
  • Satiation — The feeling of fullness that builds during a meal and signals you to stop eating.
  • Maintenance dose — The stable, ongoing dose taken once titration is complete, intended to sustain treatment effects long-term.
  • Half-life — The time it takes for half of a drug dose to be cleared from the body — determines how often a medication needs to be taken.
  • Titration — The gradual, step-by-step increase of a medication dose over time, used to reduce side effects.
  • Dual agonist — A medication that activates two hormone receptors at once — for example, tirzepatide, which targets both GLP-1 and GIP receptors.
  • Receptor agonist — A drug that binds to and activates a specific receptor, mimicking the effect of the body's natural hormone.
  • Incretin — A class of gut hormones, including GLP-1 and GIP, that trigger insulin release in response to food.
  • GIP — Glucose-dependent insulinotropic polypeptide — a second gut hormone, alongside GLP-1, that some newer medications (like tirzepatide) target together.
  • GLP-1 — A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.

Tools

tool
Shotsy
A GLP-1 tracking app for injections or pills, dose schedules, side effects, and weight. The core app is free; an optional Shotsy+ subscription adds medication level charts and health-data sync.

Resources